A paper in the journal Oncotarget has suggested that patients who have progressed on treatment with enzalutamide (Xtandi) may be good candidates for treatment with one of the checkpoint inhibitors like pembrolizumab (Keytruda), nivolumab (Opdivo), or even ipilimumab (Yervoy). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, checkpoiny, CRPC, enzalutamide, inhibitor, resistant | Leave a comment »
A new article on the Medscape Oncology web site (and again correlated with a media release sent out by the European Association for Urology [EAU] from their annual meeting in Milan, Italy) is headed “Prostate cancer vaccine shows promise.” However, the degree of that “promise” appears to be open to some question. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management | Tagged: castration, dexamethasone, multi-peptide, outcome, PSA, resistant, trial, vaccine | 7 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 